| Autor: |
Perkhofer L; Department of Internal Medicine I, Ulm University Hospital, 89081 Ulm, Germany., Golan T; Oncology Institute, Sheba Medical Center, Tel Aviv University, Tel Aviv 52621, Israel., Cuyle PJ; Digestive Oncology Department, Imelda General Hospital, 2820 Bonheiden, Belgium.; University Hospitals Gasthuisberg Leuven and KU Leuven, 3000 Leuven, Belgium., Matysiak-Budnik T; IMAD, Department of Gastroenterology and Digestive Oncology, Hôtel Dieu, CHU de Nantes, 44000 Nantes, France., Van Laethem JL; GI Cancer Unit, Erasme Hospital, Université Libre de Bruxelles, 1070 Brussels, Belgium., Macarulla T; Vall d'Hebrón University Hospital and Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain., Cauchin E; IMAD, Department of Gastroenterology and Digestive Oncology, Hôtel Dieu, CHU de Nantes, 44000 Nantes, France., Kleger A; Department of Internal Medicine I, Ulm University Hospital, 89081 Ulm, Germany., Beutel AK; Department of Internal Medicine I, Ulm University Hospital, 89081 Ulm, Germany., Gout J; Department of Internal Medicine I, Ulm University Hospital, 89081 Ulm, Germany., Stenzinger A; Institute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany., Van Cutsem E; University Hospitals Gasthuisberg Leuven and KU Leuven, 3000 Leuven, Belgium., Bellmunt J; Medical Oncology, University Hospital del Mar, 08003 Barcelona, Spain.; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA., Hammel P; Hôpital Beaujon, 92110 Clichy, France., O'Reilly EM; Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.; Department of Medicine, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Seufferlein T; Department of Internal Medicine I, Ulm University Hospital, 89081 Ulm, Germany. |
| Abstrakt: |
Impaired DNA damage repair (DDR) is increasingly recognised as a hallmark in pancreatic ductal adenocarcinoma (PDAC). It is estimated that around 14% of human PDACs harbour mutations in genes involved in DDR, including, amongst others, BRCA1/2 , PALB2 , ATM , MSH2 , MSH6 and MLH1 . Recently, DDR intervention by PARP inhibitor therapy has demonstrated effectiveness in germline BRCA1/2 -mutated PDAC. Extending this outcome to the significant proportion of human PDACs with somatic or germline mutations in DDR genes beyond BRCA1/2 might be beneficial, but there is a lack of data, and consequently, no clear recommendations are provided in the field. Therefore, an expert panel was invited by the European Society of Digestive Oncology (ESDO) to assess the current knowledge and significance of DDR as a target in PDAC treatment. The aim of this virtual, international expert meeting was to elaborate a set of consensus recommendations on testing, diagnosis and treatment of PDAC patients with alterations in DDR pathways. Ahead of the meeting, experts completed a 27-question survey evaluating the key issues. The final recommendations herein should aid in facilitating clinical practice decisions on the management of DDR-deficient PDAC. |
